Ozempic vs Zepbound: what the clinical data actually shows

What did @rickikiolbassa actually say?

The short version: not much, and that's mostly fine. @rickikiolbassa is on her third week of Zepbound at 10mg and shared that she's heard "there's better results with Zepbound" compared to Ozempic-class drugs, but immediately walked it back with "I don't know for sure." She credited her doctor for the decision and framed the whole thing as trial and error. Honest, if vague.

She's documenting a personal experience, not making clinical claims. The closest thing to a factual assertion is that Zepbound produces better results than semaglutide-based drugs like Ozempic. That one is actually worth examining, because the data is more interesting than she probably realizes.

Does the science back this up?

Surprisingly, yes, at least for weight loss. The SURMOUNT-5 trial (Jastreboff et al., 2025, New England Journal of Medicine) was the first head-to-head randomized trial comparing tirzepatide (Zepbound) directly to semaglutide (Wegovy) in adults with obesity. Tirzepatide produced about 47% greater relative weight loss. Participants on tirzepatide lost a mean of 20.2% of body weight versus 13.7% on semaglutide over 72 weeks.

Earlier indirect comparisons pointed the same direction. A network meta-analysis by Shi et al. (2022, Diabetes, Obesity and Metabolism) found tirzepatide consistently outperformed semaglutide on both weight and blood sugar endpoints. The mechanism matters here: tirzepatide activates both GIP and GLP-1 receptors, while semaglutide only hits GLP-1. That dual-agonist action appears to drive the additional efficacy, though the full picture of why GIP matters is still being worked out.

What did they get wrong (or right)?

She got the general direction right. Saying "there's better results with Zepbound" is supported by the best available head-to-head data. Credit where it's due.

What she glossed over is that "better" is context-dependent. SURMOUNT-5 compared maximally tolerated doses, which means the gap reflects best-case scenarios, not typical real-world use. Side effect profiles differ too. Tirzepatide and semaglutide have broadly similar GI side effect patterns, but individual tolerance varies significantly. Some people do better on semaglutide. The "trial and error" framing she uses is actually more accurate than she probably intended.

She also did not specify what she meant by "Zembig" (likely Wegovy or Mounjaro), which matters because Ozempic and Wegovy are both semaglutide but approved for different indications, and Mounjaro is tirzepatide approved for diabetes while Zepbound is tirzepatide approved for weight loss. These are not interchangeable comparisons, and conflating them causes real confusion for people trying to make informed decisions.

What should you actually know?

The Zepbound versus semaglutide comparison is now one of the better-studied questions in GLP-1 pharmacology. SURMOUNT-5 settled the headline, but the fine print matters: tirzepatide wins on average weight loss, but individual response varies, and not everyone reaches or tolerates the higher doses where the gap is most pronounced.

The "talk to your doctor" advice she gives is genuinely correct and not just a liability disclaimer. Drug choice depends on insurance coverage (tirzepatide is still more expensive and harder to get covered), comorbidities, prior medication history, and tolerance. A person with a history of poor GI tolerance may do better titrating semaglutide. Someone with type 2 diabetes has different approved-use considerations than someone seeking weight management alone.

• Tirzepatide (Zepbound) is a dual GIP/GLP-1 agonist. Semaglutide (Ozempic, Wegovy) is a GLP-1 agonist only.
• SURMOUNT-5 showed tirzepatide produced greater average weight loss in a direct head-to-head trial.
• Individual response still varies. Some patients do not respond as well to tirzepatide.
• Dose and indication matter when comparing brand names. Mounjaro and Zepbound are both tirzepatide but carry different FDA approvals.